{"author_name":"The Best Of BioTech IQ","author_url":"https://art19.com/shows/the-best-of-biotech-iq/episodes/53b86eef-2650-4852-a3a6-4747d6ba0fdf","description":"Dr. Morales discusses how COVID-19 affects the clinical trial supply chain, IP Strategy, and transitioning from pre-clinical to clinical.","html":"<iframe src=\"https://art19.com/shows/the-best-of-biotech-iq/episodes/53b86eef-2650-4852-a3a6-4747d6ba0fdf/embed\" style=\"width: 720px; height: 200px; border: 0 none;\" width=\"720\" height=\"200\" scrolling=\"no\" sandbox=\"allow-scripts allow-popups allow-popups-to-escape-sandbox\"></iframe>","provider_name":"ART19","provider_url":"https://art19.com","title":"#2 Guillermo Morales - CEO Innoventyx","type":"rich","version":"1.0","width":720,"height":200}